0001567619-22-000819.txt : 20220106 0001567619-22-000819.hdr.sgml : 20220106 20220106194853 ACCESSION NUMBER: 0001567619-22-000819 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220104 FILED AS OF DATE: 20220106 DATE AS OF CHANGE: 20220106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vexler Vladimir CENTRAL INDEX KEY: 0001759506 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36721 FILM NUMBER: 22516206 MAIL ADDRESS: STREET 1: 333 TWIN DOLPHIN DRIVE STREET 2: SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Coherus BioSciences, Inc. CENTRAL INDEX KEY: 0001512762 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 273615821 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: C/O DENNIS M. LANFEAR STREET 2: 333 TWIN DOLPHIN DR, SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: (650) 649-3530 MAIL ADDRESS: STREET 1: C/O DENNIS M. LANFEAR STREET 2: 333 TWIN DOLPHIN DR, SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: BioGenerics, Inc. DATE OF NAME CHANGE: 20110210 4 1 doc1.xml FORM 4 X0306 4 2022-01-04 0 0001512762 Coherus BioSciences, Inc. CHRS 0001759506 Vexler Vladimir COHERUS BIOSCIENCES, INC. 333 TWIN DOLPHIN DRIVE, SUITE 600 REDWOOD CITY CA 94065 0 1 0 0 Chief Scientific Officer Common Stock 2022-01-04 4 A 0 40000 0.00 A 115154 D Stock Option (Right to Buy) 15.94 2022-01-04 4 A 0 80000 0.00 A 2032-01-04 Common Stock 80000 80000 D Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on January 4 of each year, with the first 1/3 vesting on January 4, 2023 and with the RSUs being fully vested on January 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Includes 112,083 RSUs. Includes 1,768 shares acquired on November 15, 2021, pursuant to Issuer's employee stock purchase plan. The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. /s/ McDavid Stilwell, as Attorney-in-Fact for Vladimir Vexler 2022-01-06